← Back to all signals
RESEARCH PAPER ANALYSIS

Self-Powered Wireless Galvanic ECL Platform for On-Site Glutathione Detection.

A self-powered galvanic Cu-foam electrochemiluminescence sensor was developed for sensitive, rapid on-site detection of reduced glutathione (GSH) in human urine (LOD 1.8×10⁻⁷ M) with high recovery and good selectivity/stability.

PMID41913429
JournalACS applied materials & interfaces
Publication Date2026-04-15
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

A self-powered galvanic Cu-foam electrochemiluminescence sensor was developed for sensitive, rapid on-site detection of reduced glutathione (GSH) in human urine (LOD 1.8×10⁻⁷ M) with high recovery and good selectivity/stability.

WHY IT MATTERS

Research significance

This low-cost, portable platform enables point-of-care monitoring of GSH as an oxidative-stress biomarker relevant to Parkinson’s disease patient monitoring and stratification, but it offers limited direct mechanistic or therapeutic-discovery insights.

ABSTRACT

Source abstract

In the realm of electrochemical systems for electrochemiluminescence (ECL) analysis, reliance on an external power source, whether connected directly or through a wireless energy transfer circuit, can be limiting and inconvenient. This study reveals an innovative approach using homemade galvanized Cu foam (GCF) prepared by electrodeposition of Zinc (Zn) metal on a selected or unmasked area of Cu foam functioning as both the power source and electrode. Interestingly, simple immersion of GCF in the Luminol/H2O2 system showed approximately 1500 times higher ECL intensity than without its presence. The formation of intermediate products and generation of reactive oxygen species (ROS) during ECL are confirmed via NMR, in situ UV-vis, Raman, and EPR. The feasibility and robustness of the proposed platform were systematically validated through control experiments with noble metal-decorated Cu foam electrodes and different cathodic materials. As a proof-of-concept experiment, the prepared GCF based ECL platform is used for on-site detection of the stress biomarker reduced glutathione (GSH) in Parkinson's disease, where it shows rapid response times and unparalleled accuracy and covers an impressive range of GSH concentrations, from 0.5 × 10-6 to 1.6 × 10-4 M, with a limit of detection (LOD) at 1.8 × 10-7 M. The sensing mechanism of the ROS-scavenging behavior of GSH, leading to thiol oxidation (conversion of GSH to GSSG (oxidised GSH)) and Cu-GSH complex formation, is confirmed by UV-Vis, FT-IR, and NMR studies. The platform showed excellent practical performance with 98-102% recovery in real human urine. Interference and time-dependent ECL profile studies on various GCF electrodes further confirm the sensor's good selectivity, stability, and reproducibility. With a self-powered design, these devices eliminate the necessity for external power supplies, intricate electrochemical setups, and photomultiplier tubes (PMT), transforming their size and cost while making them accessible for scaling and miniaturization for point-of-care applications. This self-powered ECL stands at the forefront of innovation, heralding a new era of visual and ECL imaging and biosensing applications.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic